about
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complexThe immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Controlling cytomegalovirus: helping the immune system take the leadImmune biomarkers predictive of respiratory viral infection in elderly nursing home residents.Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodiesReduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infectionInhibition of cytomegalovirus infection and photothermolysis of infected cells using bioconjugated gold nanoparticlesHigh-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination.A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D LigandType 1 Interferons and NK Cells Limit Murine Cytomegalovirus Escape from the Lymph Node Subcapsular Sinus.Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?Awareness of Cytomegalovirus Infection among Pregnant Women in Geneva, Switzerland: A Cross-sectional Study.Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection agaModeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infectionThe Human Cytomegalovirus UL116 Gene Encodes an Envelope Glycoprotein Forming a Complex with gH Independently from gLInduction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunityProphylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.Congenital Cytomegalovirus: a "Now" Problem-No Really, NowDeveloping a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?Molecular and biological characterization of a new isolate of guinea pig cytomegalovirus.Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection.Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.High-throughput screening of a GlaxoSmithKline protein kinase inhibitor set identifies an inhibitor of human cytomegalovirus replication that prevents CREB and histone H3 post-translational modification.Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity.Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections.Chemokines encoded by herpesviruses.Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.Strong Cell-Mediated Immune Response to Human Cytomegalovirus Is Associated With Increased Risk of Fetal Infection in Primarily Infected Pregnant Women.Cloning, Assembly, and Modification of the Primary Human Cytomegalovirus Isolate Toledo by Yeast-Based Transformation-Associated Recombination.Breast Milk HCMV viral load is associated with the establishment of breast milk CMV-pp65-specific CD8 T cells in Human CMV infected Mothers.Congenital Cytomegalovirus Infection: Improved Understanding of Maternal Immune Responses That Reduce the Risk of Transplacental Transmission.Cytomegalovirus vaccines under clinical development
P2860
Q21089588-D1668A15-76D1-4E74-B505-3D0010C0E708Q27692570-91920E3B-CAF6-4922-B8FA-1A79B5584AC6Q33820695-86378AE9-9B2F-442D-8B0A-ECDFBA4FE3E6Q34282272-25F884D9-271C-47DF-8009-87B8F7BF6908Q34753135-E5C893AE-7509-4F31-B6BD-3C29C9989A53Q35196400-39CCAB30-B3C3-498F-A730-CF4EAEE9DDFBQ35200495-E568E435-E19D-475D-9658-268AA6F5BFD8Q35861195-7BB1B72D-4A31-4E6A-8013-834E4D6D7CB7Q35886919-87BB8E9C-9764-4050-B90B-B80B4502024EQ36135817-D0BF0600-B9B4-4135-9D7B-96DEA3DFDFD9Q36210368-E5A886F7-F5CF-42A5-9468-72DDB4716128Q36215037-5639B450-DFEF-4288-BF41-74EB8E60F15DQ36281094-2F2A29EE-7D21-49B1-89C4-58F1D8865169Q36302615-EA8377A6-F2D4-4849-B708-B65B0C150A8AQ36403590-ABB8D059-F241-4CCC-B75B-B22A82EEBEC8Q36430938-B486DA24-F783-4F6C-91EC-8CA9A3AAA1ACQ36612933-EBC62E91-46BE-490B-8AA0-C7A569546AE3Q36633558-44BFBCA1-E7AA-473E-92C2-BCBB87277361Q36830632-9449713B-7AAA-4B76-A2EB-144D6B6D9781Q36878894-F2468AC2-6FF4-42CA-8FB5-334B2EEAED07Q36977623-B1C9C9BB-7CB1-4063-9898-7D2229482DB8Q37203522-2C9831B4-7558-4EA9-AE9B-D366FBEAD052Q37409233-7FD6CF07-4BC8-488C-854A-F6DCF0843AACQ37508272-6F08788F-BDB8-4688-8219-5F4D51800EA5Q37563598-717BCCFC-7FBA-4910-98A0-50987B7B93A3Q37574334-4F8B17AD-FE47-4EBC-BE14-D26E1D116016Q37611802-0222DA53-56D8-46A8-884F-DEA69DC04193Q37651700-5DDD4442-A292-4725-9431-267F36BF6928Q38744569-405788C3-A835-4641-80D1-DB0ED8703586Q38835171-71EF2AF8-A255-4CF3-A573-2426761FA74BQ39013996-BF2D67CC-64AE-44B5-A329-D24DC4C099CAQ39296561-57598378-168C-4CD6-A6F2-55ED1C3FF607Q40059344-266A556D-805F-471A-957C-F16D92071F2BQ40067378-B0185414-6AE2-4EE0-BA46-DB1CAD5A2C78Q40295939-BCB78AAA-4945-4F9D-A3B9-14D74470B170Q41107880-01E2CA7D-2822-4E0E-9473-4EB0F967B40CQ41921793-6F53680E-DE64-4155-9427-EA1B804D5FB6Q41926403-33DA8946-A42C-4C67-B449-5812DDD470E3Q41987283-53AAB9F4-8267-4D8E-8585-0EE54CC113C9Q42380888-F690E2FF-D53F-4D79-8844-4484B7CD7A9F
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Priorities for CMV vaccine development
@ast
Priorities for CMV vaccine development
@en
type
label
Priorities for CMV vaccine development
@ast
Priorities for CMV vaccine development
@en
prefLabel
Priorities for CMV vaccine development
@ast
Priorities for CMV vaccine development
@en
P2093
P2860
P1433
P1476
Priorities for CMV vaccine development
@en
P2093
Catherine A Laughlin
Edward S Mocarski
Jennifer S Read
Mark R Schleiss
Paul D Griffiths
Per Ljungman
Robert F Pass
Stephanie R Bialek
Suresh B Boppana
P2860
P356
10.1016/J.VACCINE.2013.09.042
P407
P577
2013-10-13T00:00:00Z